Tie Zhou, Shengfei Qin, Weidong Xu, Shouyan Tang, Guanghua Chen, Song Li, Jianguo Hou, Xu Gao, Guowei Shi, Zhongquan Sun, Jie Jin, Lijun Chen, Weibing Sun, Ben Liu, Jingen Wang, Qinggui Meng, Dongwen Wang, Zhiquan Hu, Dalin He, Yong Yang, Xishuang Song, Cheng Fu, Yinhuai Wang, Dingwei Ye, Wei Zhang
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100 mg, 200 mg, 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR), and time to PSA and radiographic progression...
March 15, 2023: International Journal of Cancer. Journal International du Cancer